CSU Ventures boosted its licensing income by more than two-fold and established six new spinouts during the 2018-19 academic year.

Returning investor BGI took part in a series B round for the cancer diagnostics technology developer that included fellow corporate UEC.

Returning investors Agilent Technologies and Alexandria Venture Investments chipped into a $12.2m round for the DNA synthesis technology developer.

Immuno-oncology startup Stipe, based on Aarhus research, has secured $22m in a round co-led by Novo Seeds, after being incubated at Novo's BioInnovation Institute.

The UC Berkeley-founded gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

OSF Healthcare and Wanxiang both returned for the extension having also contributed to a $45m first close for the patient management platform developer.

The Pfizer and Chiesi-backed gene therapy developer plans to use the IPO proceeds to advance treatments for Fabry disease, cystic fibrosis and ophthalmological diseases.

The medical research provider secured $32.7m in a round backed by existing investor Holtzbrinck Digital that will fund its entry into new markets.

Immuno-oncology startup Stipe has secured $22m in a round co-led by Novo Seeds, after being incubated at Novo's BioInnovation Institute.